Found: 11
Select item for more details and to access through your institution.
CLINICAL FEATURES, TREATMENT AND OUTCOME OF NEUROLYMPHOMATOSIS: SINGLE INSTITUTION EXPERIENCE.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 269, doi. 10.1002/hon.80_2630
- By:
- Publication type:
- Article
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 37, doi. 10.1002/hon.6_2629
- By:
- Publication type:
- Article
OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 231, doi. 10.1002/hon.44_2630
- By:
- Publication type:
- Article
PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)‐POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 48, doi. 10.1002/hon.18_2629
- By:
- Publication type:
- Article
CLINICAL FEATURES, TREATMENT AND OUTCOME OF NEUROLYMPHOMATOSIS: SINGLE INSTITUTION EXPERIENCE.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 269, doi. 10.1002/hon.80_2630
- By:
- Publication type:
- Article
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 37, doi. 10.1002/hon.6_2629
- By:
- Publication type:
- Article
OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 231, doi. 10.1002/hon.44_2630
- By:
- Publication type:
- Article
PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)‐POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 48, doi. 10.1002/hon.18_2629
- By:
- Publication type:
- Article
GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL STUDY FROM NORTH AMERICA.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 55, doi. 10.1002/hon.2437_40
- By:
- Publication type:
- Article
BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE).
- Published in:
- Hematological Oncology, 2017, v. 35, p. 213, doi. 10.1002/hon.2438_78
- By:
- Publication type:
- Article
HOST GENETIC VARIATION IN THE TNF AND NF-ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 151, doi. 10.1002/hon.2438_4
- By:
- Publication type:
- Article